Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration
- DOI
- 10.1001/jamaophthalmol.2020.5053
- Published
- 2021-01-01
- Container
- JAMA Ophthalmology
- Publisher
- American Medical Association (AMA)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1001/jamaophthalmol.2020.5053,
title = {Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration},
author = {Se Joon Woo and Miroslav Veith and Jan Hamouz and Jan Ernest and Dominik Zalewski and Jan Studnicka and Attila Vajas and Andras Papp and Vogt Gabor and James Luu and Veronika Matuskova and Young Hee Yoon and Tamás Pregun and Taehyung Kim and Donghoon Shin and Neil M. Bressler},
year = {2021},
journal = {JAMA Ophthalmology},
doi = {10.1001/jamaophthalmol.2020.5053},
url = {https://doi.org/10.1001/jamaophthalmol.2020.5053}
}RIS
TY - JOUR TI - Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration AU - Se Joon Woo AU - Miroslav Veith AU - Jan Hamouz AU - Jan Ernest AU - Dominik Zalewski AU - Jan Studnicka AU - Attila Vajas AU - Andras Papp AU - Vogt Gabor AU - James Luu AU - Veronika Matuskova AU - Young Hee Yoon AU - Tamás Pregun AU - Taehyung Kim AU - Donghoon Shin AU - Neil M. Bressler PY - 2021 JO - JAMA Ophthalmology DO - 10.1001/jamaophthalmol.2020.5053 UR - https://doi.org/10.1001/jamaophthalmol.2020.5053 ER -
APA
Woo, S. J., Veith, M., Hamouz, J., Ernest, J., Zalewski, D., Studnicka, J., Vajas, A., Papp, A., Gabor, V., Luu, J., Matuskova, V., Yoon, Y. H., Pregun, T., Kim, T., Shin, D., & Bressler, N. M. (2021). Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2020.5053
Source records
- crossref · retrieved 2026-09-26T09:45:37.546Z